145 related articles for article (PubMed ID: 38716645)
1. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis.
Dong P; Yan Y; Yang L; Wu D; Wang H; Lv Y; Zhang J; Yu X
J Oncol; 2022; 2022():2085267. PubMed ID: 36213828
[TBL] [Abstract][Full Text] [Related]
4. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.
Wang H; Liang S; Yu Y; Han Y
Front Oncol; 2024; 14():1276549. PubMed ID: 38292925
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis.
Wang Z; Shao C; Wang Y; Duan H; Pan M; Zhao J; Wang J; Ma Z; Li X; Yan X
Int J Surg; 2022 Aug; 104():106767. PubMed ID: 35840049
[TBL] [Abstract][Full Text] [Related]
11. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
Zhu J; Leng X; Gao B; Wang B; Zhang H; Wu L; Ma J; Tan Y; Peng L; Han Y; Wang Q
Front Immunol; 2022; 13():1041233. PubMed ID: 36591306
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.
Xu H; Li T; Shao G; Wang W; He Z; Xu J; Qian Y; Liu H; Ge H; Wang L; Zhang D; Yang L; Li F; Xu Z
Front Immunol; 2023; 14():1193614. PubMed ID: 37426646
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Yan Y; Wu D; Wang W; Lv Y; Yang L; Liu Y; Dong P; Yu X
J Cancer Res Ther; 2024 Apr; 20(2):633-641. PubMed ID: 38687934
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
[TBL] [Abstract][Full Text] [Related]
17. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
19. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
